Moderna Burns Cash, Suffers Fresh Vaccine Setback
Moderna Inc. (NASDAQ: MRNA ) on Friday reported a second-quarter loss of $1.97 per share, beating the consensus loss of $2.10 per share. The COVID-19 vaccine maker reported sales of $145 million, better than the Wall Street estimate of $102.998 million. Lower COVID vaccine sales in the U.S. and South America were offset by deliveries in the U.K. under a long-term strategic government partnership and higher stand-ready manufacturing and collaboration revenue. Revenue was $87 million in the U.S. and $58 million in international markets. Read Also: Moderna Strengthens Commercial Strategy As Pipeline Advances R&D Spending Declines as Moderna Advances Pipeline R&D expenses for the second quarter of 2026 were $651 million, a 7% decrease year over year, primarily driven by lower clinical development costs following the wind-down of several late-stage programs. Cash, cash equivalents and inve...
Moderna Inc. 10 per share. 998 million. S.
K. under a long-term strategic government partnership and higher stand-ready manufacturing and collaboration revenue. S. and $58 million in international markets.
Read Also: Moderna Strengthens Commercial Strategy As Pipeline Advances R&D Spending Declines as Moderna Advances Pipeline R&D expenses for the second quarter of 2026 were $651 million, a 7% decrease year over year, primarily driven by lower clinical development costs following the wind-down of several late-stage programs. 5 billion as of March 31, 2026. The decrease primarily reflected cash used to fund operations, continued investment in research and development, and advancement of its pipeline. The company subsequently paid $950 million in July 2026 related to the litigation settlement announced in the first quarter of 2026.
089 billion. S. and approximately 50% international. Moderna expects approximately 55% of its second half 2026 revenue to be recognized in the third quarter.
Flu Vaccine Decision Nears as Norovirus Program Continues The company anticipates potential approval of its fifth product with the August 5 PDUFA date for mFLUSIVA, the company’s seasonal influenza vaccine candidate. On Friday, Moderna also said its norovirus vaccine candidate, mRNA-1403, did not meet statistical criteria for early success at the Phase 3 interim analysis, and the company is preparing to enroll an additional cohort. 37 at the time of publication on Friday, according to Pro data. Image via Shutterstock Read Also: Jim Cramer Says INTC Stock ‘Belongs at $110,’ Blames Situational Awareness Blowup for Intel’s Post-Earnings ’Hideous Selling’